Zero Discrimination Day
#ZERO DISCRIMINATION
1 March 2019
Accessed: 19.10.2019
Supplement Article
www.jaids.com J Acquir Immune Defic Syndr Volume 78, Supplement 1, August 15, 2018
Revised working paper following AVAREF meeting February 2019.
WHO has published a roadmap aiming to coordinate partners’ actions and contributions to the licensing and roll-out of Merck’s Ebola vaccine (VSV-ZEBOV) in African countries. The vaccine was developed during the West Africa Ebola epi...demic of 2014-2016, during which more than 11 000 people lost their lives to the disease. The vaccine was tested in European and African countries at the time and is currently used under an “expanded access” protocol in the Democratic Republic of Congo.
WHO will expedite prequalification and licensing of the vaccine for use in countries at risk of Ebola outbreaks and will coordinate work between those countries’ regulatory authorities and the European Medicines Agency and the US Food and Drug Administration.
more
Problems with care for older people with dementia in Australia “Fading Away”: How Aged Care Facilities in Australia Chemically Restrain Older People with Dementia
AIDS Behav (2017) 21:S23–S33 DOI 10.1007/s10461-016-1670-9
USAID Office of HIV/AIDS
March 8-9, 2016
Information Note
Advice for countries using or planning
to introduce dual HIV/syphilis RDT in antenatal services and other testing sites.
WHO/RHR/17.01
Policy Brief
HIV testing services
December 2016
WHO/HIV/2016.21
Policy brief. HIV testing services (HTS) and anti-retroviral therapy (ART) have been scaled up substantially. It is estimated that, globally, nearly 80% of people with HIV now know their status. With the offer of immediate ART initiation and improved treatment options, access to and uptake of treatm...ent have increased, too. Now, most people with HIV who know their status are obtaining treatment and care.
In response to these changes in the global HIV epidemic, WHO is encouraging countries to use three consecutive reactive tests for an HIV-positive diagnosis as their treatment-adjusted prevalence and national HTS positivity fall below 5% .
more
Policy brief.
Globally, one in five people with HIV are unaware of their status, despite considerable scale up of HIV testing, treatment and prevention services. Many of those unreached by HIV testing services (HTS) are from key populations, partners of people with HIV and, in Eastern and southern ...Africa, men and young people. Improving the availability, accessibility, friendliness and quality of services is important to address these testing gaps.
At the same time, tools and interventions that increase the demand for HTS are needed to reach people who are uninformed about HTS options and advances in treatment and prevention, people who are not motivated to seek HTS and those who are hesitant to test because of fear of an HIV diagnosis or other reasons.
more
WAHA International’s mHealth programme addresses several barriers to maternal and neonatal care, including: a lack of information at the community level about locally available services; a large distance from services and a lack of affordable transport for patients; and ineffective communication b...etween community-based and facility-based health workers.
more
Veterinarians are leaders and stewards in preserving the effectiveness of antibiotics for animals and people. Working with animal owners and producers, veterinarians can slow antibiotic resistance by implementing disease prevention strategies and improving the use of antibiotics while also guarante...eing high-quality medical care for animal patients.
more
BMJ Global Health Vol.4 (2019 no.4
The Drug Resistance Index (DRI) is proposed as measure of antibiotic effectiveness in a given country, by combining, in a single metric the use of various antibiotic groups and the resistance proportions of several pathogens.It is a complicated measure that gives ...results that cannot be understood by common knowledge and logic. The DRI conveys a wrong message.
more